Company news

Syntara Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

After FDA Review PXS Accelerates Plans for Combination Study

April 11, 2023

PXS announces positive interim data from myelofibrosis trial

October 18, 2022

Investor Presentation

October 18, 2022

PXS Releases Promising Interim Data from Skin Scarring Study

September 25, 2022

PXS to Receive Stg2.9m from Parkinsons UK for New Trial

August 31, 2022

Aptar Pharma Pays PXS Us$5m to Acquire Orbital Technology

August 4, 2022

Clarification Announcement

May 13, 2022

Appendix 4C Quarterly Cash Flow Report

April 28, 2022

Response to ASX Aware Query

January 10, 2022

PXS Collaborators Receive Government Grants of $1.4m

January 5, 2022

Share Purchase Plan

December 20, 2021

Security Purchase Plan

November 24, 2021

FDA Clears PXS Cancer Drug for Phase 2 Liver Cancer Study

November 8, 2021

Appendix 4C Cash Flow Report

October 27, 2021

PXS Doses First Patient in Phase 2 Bone Marrow Cancer Trial

October 13, 2021

PXS Cleared to Progress to Phase 2 Bone Marrow Cancer Trial

October 4, 2021

Pharmaxis Treatment to Prevent Wound and Burns Scars Clears

August 30, 2021

PXS Grants Exclusive Option to Develop High Payload Inhaler

August 16, 2021

PXS Drug Decreases Tumour Burden in Liver Cancer Model

August 4, 2021

PXS Sells Australian Distribution Rights for A$2m

June 30, 2021

PXS Announces First Results in Bone Marrow Cancer Trial

June 29, 2021

Quarterly Activity Report

April 30, 2021

Appendix 4C - quarterly

April 30, 2021

Sale of Russian Distribution Rights

April 13, 2021

First Patient Enrolled - Clinical Trial for Cancer Treatment

February 21, 2021

Pharmaxis Exports CF Drug to US - US$3 Million Milestone

February 8, 2021

Quarterly Activity Report - December 2020

January 28, 2021

Pharmaxis Receives US$7m milestone from Chiesi

December 29, 2020

Pharmaxis Prioritises Clinical Program on Myelofibrosis

November 1, 2020

September Quarter 2020 Activity Report

October 29, 2020

Boehringer Ingelheim discontinues development of BI 1467335

September 6, 2020

Pharmaxis Awarded $1M Australian Government Grant

September 2, 2020

FDA Gives Green Light to Start Myelofibrosis Phase 2 Study

August 19, 2020

US$7 million Bronchitol Launch Milestone Brought Forward

August 4, 2020

Fourth Quarter Activity Report

July 30, 2020

Pharmaxis Quarterly Shareholder Update - March 2020

April 29, 2020

PXS Cancer Drug Ready to Commence Phase 2 Studies Q4 2020

April 27, 2020

Quarterly Shareholder Update - December 2019

January 30, 2020

Pharmaxis Business Plan Update

December 17, 2019

Quarterly Shareholder Update - September 2019

October 30, 2019

FDA Provides Guidance on Bronchitol Approval Steps

October 27, 2019

Pharmaxis Receives $6.2m R&D Tax Incentive

October 16, 2019

Quarterly Shareholder Update - June 2019

July 25, 2019

Pathway to US Bronchitol Approval Clarified in FDA Response

June 19, 2019

US Advisory Committee Positive Recommendation on Bronchitol

May 8, 2019

Quarterly Shareholder Update - March 2019

April 29, 2019

Pharmaxis Commences Phase 1 LOX Clinical Trial

February 21, 2019

Quarterly Shareholder Update - December 2018

January 29, 2019

Pharmaxis Announces LOXL2 Program Phase 2 Ready

January 16, 2019

Pharmaxis announces resubmission of bronchitol nda in usa

December 19, 2018

← Newer news releases · Older news releases →

Decks

The 5 newest of 39 decks. Every deck is listed under its year.